Spotlight Series on Hepatitis C


Which Hepatitis C Treatment to Start in 2017

August 17, 2017


Rapid-Fire Approvals and a 'Living Document' Guidance Document

Rapid-Fire Approvals and a "Living Document" Guidance Document

The two medical associations responsible for crafting HCV treatment guidelines are the American Association for the Study of Liver Disease (AASLD) and the Infectious Disease Society of America (IDSA). Together, these associations have crafted what they call a "living document," which is posted online and updated continually to reflect the rapidly changing treatment landscape. Still, as of August 2017, some newer drugs such as sofosbuvir/velpatasvir/voxilaprevir had not been incorporated into the document.

Yet, despite the rapid-fire approvals, almost all of the prior guidance holds true. For example, the guidelines recommend treatment for all HCV-infected people, except in extreme circumstances such as terminal illness. In addition, the guidelines no longer recommend daily sofosbuvir (Sovaldi) with ribavirin or pegylated interferon (even in combination) due to the plethora of better alternatives now available.

Image credit: Comstock for Stockbyte via Thinkstock.

Related Stories

The Need for a Codified Hepatitis C Care Continuum
Could the HIV Treatment-as-Prevention Model Work for Hepatitis C?

This article was provided by


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.